Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Reports: Alexion | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Reports: Alexion

Soliris continues to rise

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Alexion 1Q13

1Q Revenues: $339 million (+38%)

1Q Earnings: $82 million (+81%)

Comments: Sales of Soliris climbed 38% to $339 million, adding patients for both paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS) indications. R&D expenses climbed 64% to $75 million as the company advanced five clinical programs, including one with Soliris.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters